Literature DB >> 31482500

Enzymes in Metabolic Anticancer Therapy.

Maristella Maggi1, Claudia Scotti2.   

Abstract

Cancer treatment has greatly improved over the last 50 years, but it remains challenging in several cases. Useful therapeutic targets are normally unique peculiarities of cancer cells that distinguish them from normal cells and that can be tackled with appropriate drugs. It is now known that cell metabolism is rewired during tumorigenesis and metastasis as a consequence of oncogene activation and oncosuppressors inactivation, leading to a new cellular homeostasis typically directed towards anabolism. Because of these modifications, cells can become strongly or absolutely dependent on specific substrates, like sugars, lipids or amino acids. Cancer addictions are a relevant target for therapy, as removal of an essential substrate can lead to their selective cell-cycle arrest or even to cell death, leaving normal cells untouched. Enzymes can act as powerful agents in this respect, as demonstrated by asparaginase, which has been included in the treatment of Acute Lymphoblastic Leukemia for half a century. In this review, a short outline of cancer addictions will be provided, focusing on the main cancer amino acid dependencies described so far. Therapeutic enzymes which have been already experimented at the clinical level will be discussed, along with novel potential candidates that we propose as new promising molecules. The intrinsic limitations of their present molecular forms, along with molecular engineering solutions to explore, will also be presented.

Entities:  

Keywords:  Arginase; Arginine deaminase; Asparaginase; Cancer addictions; Glutaminase

Mesh:

Substances:

Year:  2019        PMID: 31482500     DOI: 10.1007/978-981-13-7709-9_9

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  158 in total

1.  Hyperthermophilic asparaginase mutants with enhanced substrate affinity and antineoplastic activity: structural insights on their mechanism of action.

Authors:  Saurabh Bansal; Ankit Srivastava; Goutam Mukherjee; Ramendra Pandey; Anita Kamra Verma; Prashant Mishra; Bishwajit Kundu
Journal:  FASEB J       Date:  2011-12-13       Impact factor: 5.191

2.  Targeted cancer therapies.

Authors:  Saurabh Aggarwal
Journal:  Nat Rev Drug Discov       Date:  2010-06       Impact factor: 84.694

Review 3.  A Comprehensive Review on L-Asparaginase and Its Applications.

Authors:  Tahira Batool; Essam A Makky; Muna Jalal; Mashitah M Yusoff
Journal:  Appl Biochem Biotechnol       Date:  2015-11-07       Impact factor: 2.926

4.  Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4.

Authors:  Anne L Angiolillo; Reuven J Schore; Meenakshi Devidas; Michael J Borowitz; Andrew J Carroll; Julie M Gastier-Foster; Nyla A Heerema; Taha Keilani; Ashley R Lane; Mignon L Loh; Gregory H Reaman; Peter C Adamson; Brent Wood; Charlotte Wood; Hao W Zheng; Elizabeth A Raetz; Naomi J Winick; William L Carroll; Stephen P Hunger
Journal:  J Clin Oncol       Date:  2014-10-27       Impact factor: 44.544

Review 5.  Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future.

Authors:  Vassilios I Avramis; Eduard H Panosyan
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

6.  Evolutionary relationships among pyridoxal-5'-phosphate-dependent enzymes. Regio-specific alpha, beta and gamma families.

Authors:  F W Alexander; E Sandmeier; P K Mehta; P Christen
Journal:  Eur J Biochem       Date:  1994-02-01

7.  In-vivo evaluation of human recombinant Co-arginase against A375 melanoma xenografts.

Authors:  Vaidehi Agrawal; Jung Hee Woo; Jeremy P Mauldin; Everett M Stone; Cynthia J Meininger; Chanhee Jo; Keri Kleypas; Eugene P Frenkel; Arthur E Frankel
Journal:  Melanoma Res       Date:  2014-12       Impact factor: 3.599

8.  Mitochondria as biosynthetic factories for cancer proliferation.

Authors:  Christopher S Ahn; Christian M Metallo
Journal:  Cancer Metab       Date:  2015-01-25

9.  Exploiting tumour addiction with a serine and glycine-free diet.

Authors:  Ivano Amelio; Gerry Melino; Christian Frezza
Journal:  Cell Death Differ       Date:  2017-06-02       Impact factor: 15.828

Review 10.  Serine and glycine metabolism in cancer.

Authors:  Ivano Amelio; Francesca Cutruzzolá; Alexey Antonov; Massimiliano Agostini; Gerry Melino
Journal:  Trends Biochem Sci       Date:  2014-03-20       Impact factor: 13.807

View more
  7 in total

1.  Structural Aspects of E. coli Type II Asparaginase in Complex with Its Secondary Product L-Glutamate.

Authors:  Maristella Maggi; Claudia Scotti
Journal:  Int J Mol Sci       Date:  2022-05-25       Impact factor: 6.208

Review 2.  Metabolism of Amino Acids in Cancer.

Authors:  Zhen Wei; Xiaoyi Liu; Chunming Cheng; Wei Yu; Ping Yi
Journal:  Front Cell Dev Biol       Date:  2021-01-12

3.  Revealing Escherichia coli type II L-asparaginase active site flexible loop in its open, ligand-free conformation.

Authors:  Maristella Maggi; Massimiliano Meli; Giorgio Colombo; Claudia Scotti
Journal:  Sci Rep       Date:  2021-09-23       Impact factor: 4.379

Review 4.  Metabolomics of Breast Cancer: A Review.

Authors:  Ramadevi Subramani; Seeta Poudel; Kenneth D Smith; Adriana Estrada; Rajkumar Lakshmanaswamy
Journal:  Metabolites       Date:  2022-07-13

Review 5.  Amino Acid Metabolic Vulnerabilities in Acute and Chronic Myeloid Leukemias.

Authors:  Aboli Bhingarkar; Hima V Vangapandu; Sanjay Rathod; Keito Hoshitsuki; Christian A Fernandez
Journal:  Front Oncol       Date:  2021-07-01       Impact factor: 6.244

6.  Generalized enzymatic mechanism of catalysis by tetrameric L-asparaginases from mesophilic bacteria.

Authors:  Pawel Strzelczyk; Di Zhang; Marzena Dyba; Alexander Wlodawer; Jacek Lubkowski
Journal:  Sci Rep       Date:  2020-10-15       Impact factor: 4.996

7.  Arginine deprivation alters microglial polarity and synergizes with radiation to eradicate non-arginine-auxotrophic glioblastoma tumors.

Authors:  Nabil Hajji; Juan Garcia-Revilla; Manuel Sarmiento Soto; Richard Perryman; Jake Symington; Chad C Quarles; Deborah R Healey; Yijie Guo; Manuel Luis Orta-Vázquez; Santiago Mateos-Cordero; Khalid Shah; John Bomalaski; Giulio Anichini; Andreas G Tzakos; Timothy Crook; Kevin O'Neill; Adrienne C Scheck; Jose Luis Venero; Nelofer Syed
Journal:  J Clin Invest       Date:  2022-03-15       Impact factor: 14.808

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.